RVMD

Revolution Medicines

October 8, 2026 · intraday

Rarity

1.91

Peak move

−9.96%

Float cap

$34.4B

Revolution Medicines is a late-stage clinical oncology company developing oral targeted therapies for patients with RAS-addicted cancers, including pancreatic and lung tumors. Its pipeline is built on a tri-complex RAS(ON) inhibitor platform, led by daraxonrasib, zoldonrasib, elironrasib and RMC-5127, which are designed to block the active, cancer-driving forms of RAS proteins. Its customers today are clinical trial sites, research collaborators and, prospectively, oncology treatment centers.

• analyst_ratingOct 8

  RBC Capital raised its price target on Revolution Medicines to $259 from $251 and kept an Outperform rating, in a research note adjusting models and previewing Q3 biotech results.

  Webmarketscreener.comWebtipranks.com
• analyst_ratingOct 7

  Truist Securities set a $240 price target on Revolution Medicines and maintained a Buy rating, up from $239.

  Webmarketbeat.comWebstockanalysis.com
• analyst_ratingOct 6

  LifeSci Capital analyst Charles Zhu maintained a Buy rating on Revolution Medicines with an unchanged $315 price target, citing ESMO GI 2026 data and the Phase 3 RASolute 309 trial initiation.

  Webtipranks.com
• reg_fd_disclosureOct 5

  Revolution Medicines began treating patients in the global randomized Phase 3 RASolute 309 trial of RASONQUE (daraxonrasib) plus zoldonrasib versus gemcitabine/nab-paclitaxel as first-line therapy for metastatic RAS G12D pancreatic adenocarcinoma, with dual primary endpoints of PFS and overall survival.

  Webhk.marketscreener.comWebglobenewswire.comWebir.revmed.com
• analyst_ratingSep 9 · 23:17 ET

  Stifel raised its price target on Revolution Medicines to $230 from $215 while maintaining a Buy rating.

  Webitiger.com